TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD

Their core work

TRDF is the technology transfer and research commercialization arm of the Technion — Israel Institute of Technology, one of the world's leading science and engineering universities. It manages EU-funded research across an exceptionally broad range of disciplines, from biomedical imaging and cancer therapeutics to computational geometry, materials science, and synthetic biology. The foundation channels Technion's deep bench of researchers into collaborative European projects, primarily through Marie Skłodowska-Curie fellowships and ERC Proof of Concept grants that bridge fundamental research and early-stage application. Its H2020 portfolio reflects a university-wide capability rather than a single focused lab, spanning life sciences, nanotechnology, computer vision, and chemistry.

What they specialise in

How they've shifted over time

In the early period (2015–2018), TRDF's projects concentrated on nanotechnology-enabled disease detection — breath sensors, microfluidics, ultrasonic drug delivery, and lung screening — alongside scattered contributions to cultural heritage digitization and microscopy. From 2019 onward, the portfolio shifted toward deeper life sciences (cell biology, muscle regeneration, epigenetics, synthetic biology) and computational methods (3D deep learning, cloud-based BIM, digital twins), while maintaining the biomedical thread through MRI-based cancer monitoring. The overall trajectory shows a move from hardware-centric sensor projects toward more fundamental biological research and computational modelling.

TRDF is deepening its life science and computational biology capabilities while maintaining biomedical imaging expertise — future partners should expect strong interest in projects combining biological mechanisms with advanced imaging or data analysis.

How they like to work

TRDF acts primarily as a project coordinator (9 of 19 projects), mostly leading small MSCA fellowship and ERC Proof of Concept grants rather than large multi-partner consortia. Its 6 third-party appearances suggest Technion researchers are frequently brought in as subcontracted experts on larger projects led by others. With 76 unique partners across 19 countries, the network is broad but shallow — typical of a major research university that forms project-specific partnerships rather than repeated collaborations with a core group.

TRDF has collaborated with 76 distinct partners across 19 countries, reflecting the Technion's extensive international research network. As an Israeli institution, it bridges European and Middle Eastern research ecosystems, offering non-EU partners a well-connected entry point into H2020 consortia.

What sets them apart

As the R&D foundation of one of the world's top 100 universities, TRDF provides access to Technion's full spectrum of scientific talent — a single partnership can tap into biomedical engineering, computer science, chemistry, and materials science. Unlike specialized research institutes, TRDF can field researchers across nearly any STEM discipline, making it particularly valuable for multidisciplinary consortia. Its Israel-based perspective also brings non-European research networks and industry connections that most EU partners cannot offer.

Highlights from their portfolio

• CBIM
  Largest single grant (EUR 527,002) and coordinator role — an ERC Proof of Concept bringing building information modelling to cloud-based digital twin applications.
• TheraSonix
  Distinctive combination of genetic engineering with ultrasonic imaging for targeted drug delivery into tumors using genetically encoded gas nanostructures.
• triloci-seq
  Pioneering work on triple helix DNA/RNA structures and Hoogsteen interactions — a frontier area in synthetic biology with potential implications for gene regulation and therapeutics.